A research team led by Albert Einstein College of Medicine scientists has developed a new strategy to engineer immune cells ...

Consider the case of patient WB, a 79-year-old male with recurrent diffuse large B cell lymphoma. He was referred for ...

Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically ...

FACE binds to CD71 on the T‑cell surface in CAR T cell preparation, and post-infusion, the same FACE molecules attach to CD71 on leukemia cells.

The approach relies on a specially engineered scaffold that links three naturally occurring cytokines known to promote immune memory.

This Collection provides updated research from the Immune cell engineering for cancer therapy 2024 Collection. Chimeric antigen receptor (CAR) T cell therapies have revolutionized the treatment of ...

Stylus Medicine, a member of BioSpace’s NextGen Class of 2026, launched in May 2025 to develop new, less complex genetic medicines. The company’s in vivo approach has attracted “intense” interest from ...

CAR T-cell therapy shows promise for SCLC, but significant barriers, such as tumor heterogeneity and immunosuppression, must be addressed. Identifying tumor-selective antigens like CDH17, GD2, and ...

Among the most promising tools of cancer therapy, engineered immune cells known as chimeric antigen-receptor (CAR) T cells have already transformed the treatment of blood cancers. Yet, despite their ...

A Phase 1 trial testing TG Therapeutics' CAR T-cell therapy azer-cel in progressive forms of MS is now recruiting across ...

Please provide your email address to receive an email when new articles are posted on . CAR T-cell therapy for cancer may be associated with new-onset autoimmune disease. Autoimmune events in after ...